체부 백선 시장 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the tinea corporis market size is expected to increase from USD 15.11 billion in 2025 to USD 15.75 billion in 2026 and reach USD 19.44 billion by 2031, growing at a CAGR of 4.28% over 2026-2031.

This report is Segmented by Drug Class (Azoles, Allylamines and Benzylamines, and More), by Formulation (Creams and Ointments, Gels and Lotions, and More), by Patient Demographics (Pediatrics, Adults, Geriatrics), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Drug Stores, and More), and Geography (North America, Europe, Asia-Pacific, and More). Forecasts are in Value (USD).

Global Tinea Corporis Market Trends and Insights

Persistent Burden of Superficial Dermatophytosis

Tinea corporis was the most common presentation in a multicenter Indian study, representing 41% of dermatophytosis cases and supporting the Tinea corporis market demand. Moreover, tinea cruris at 31% and tinea pedis at 15%, which shows the relative importance of body-ringworm treatment demand. Global Burden of Disease data showed the highest absolute incidence among children aged 5 to 9 years, while disability-adjusted life-year rates were highest among people aged 95 years and older. This age pattern supports demand at both ends of the population and adds to treatment needs as populations age. The 2025 World Health Assembly resolution may encourage national programs to improve surveillance, diagnostics, and treatment access for fungal skin diseases.

Expanding OTC Access and Self-Care Treatment

Within the Tinea corporis market, FDA OTC monograph reform is streamlining the framework for topical antifungal ingredients such as clotrimazole and terbinafine. The framework can lower entry barriers for branded and private-label products that meet the relevant monograph conditions. Pharmacy chains can serve people who have limited access to primary care, particularly outside major urban centers. Wider shelf availability also makes self-treatment easier for people with uncomplicated symptoms. Tele-dermatology and pharmacy links can connect a video consultation with direct delivery of OTC or prescription treatment. This model can shorten the interval between diagnosis and treatment, which can support completion of the recommended course.

Terbinafine and Multidrug Resistance in Emerging Dermatophytes

The Tinea corporis market faces a 2025 multinational genomic finding of terbinafine resistance in 70% of T. indotineae isolates. The study found that all isolates clustered in one monophyletic lineage, supporting a single evolutionary origin and continuing clonal spread. A United Kingdom review found treatment failure in 31.8% of documented cases and inadequate itraconazole response in 4.5% of cases. This reduces the reliability of azoles as a fallback when terbinafine is ineffective. National antifungal stewardship frameworks are evolving, but standardized minimum inhibitory concentration breakpoints for T. indotineae remain absent in many national pharmacopeias.

Other drivers and restraints analyzed in the detailed report include:

1. Rising Detection of Recalcitrant and Resistant Infections
2. Hot-Humid Exposure, Occlusive Clothing, and Dense Contact Networks
3. Diagnostic Misclassification and Steroid-Modified Tinea

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Azoles held 42.2% of demand in 2025, giving them the leading position in the Tinea corporis market. Their position reflects broad-spectrum activity, established OTC availability, and clinical familiarity with clotrimazole and miconazole. Itraconazole has drawn renewed attention for T. indotineae infections when terbinafine is ineffective. That use adds prescription demand to a class long associated with topical self-care products. Allylamines and benzylamines are forecast to grow at a 5.7% CAGR through 2031.

Terbinafine and naftifine have fungicidal activity that can support shorter treatment courses than fungistatic azoles in uncomplicated cases. Shorter courses can improve adherence and reduce the period in which recurrence may occur. Polyenes, including amphotericin B, remain a niche option for immunocompromised patients with severe cutaneous involvement. Anti-infective combinations, especially fixed-dose steroid-antifungal products, remain widely used in South Asia and Southeast Asia but face growing regulatory scrutiny. The Tinea corporis industry is shaped by formulation patents and delivery improvements, which help branded suppliers protect value where generic active ingredients face price pressure.

Creams and ointments held 48.3% of demand in 2025, reflecting their broad formulary presence and familiar use by patients and pharmacists. They remain practical for many body sites and are available across branded, generic, and retailer-owned product ranges. Sprays and solutions are forecast to grow at a 5.9% CAGR through 2031. In the Tinea corporis market, these formats can support no-touch application on large areas, hairy sites, and intertriginous areas where creams may be harder to spread consistently. Their fast-drying profile can also reduce the practical burden of repeated application.

A 2026 peer-reviewed study reported 91.4% entrapment efficiency for a luliconazole-loaded microsponge gel and 83.7% in vitro drug release over 12 hours. The formulation showed prolonged dermal retention and minimal irritation, which are relevant for once-daily topical use. A separate 2026 bifonazole film-forming spray study reported 11.1-second film formation and T80 release at 8.7 hours. Gels and lotions serve intermediate needs, while shampoos and washes are used for scalp and confluent body areas where liquid contact supports broader coverage.

Complete Report Scope:

• By Drug Class
  • Azoles
  • Allylamines and Benzylamines
  • Polyenes
  • Steroids
  • Anti-Infective Combinations
  • Other Antifungal Classes
• By Formulation
  • Creams and Ointments
  • Gels and Lotions
  • Sprays and Solutions
  • Powders
  • Shampoos and Washes
  • Other Formulations
• By Patient Demographics
  • Pediatrics
  • Adults
  • Geriatrics
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies and Drug Stores
  • Online Pharmacies
  • Specialty Pharmacies
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 39.2% of the Tinea corporis market share in 2025. The region has a mature OTC system, pharmacy availability, and increasing tele-dermatology use. FDA OTC monograph reform continues to guide the conditions for labeling and marketing topical antifungal products. A 2025 Medicaid study reported an incidence of 79.1 cases per 10,000 person-years among approximately 6.8 million enrollees. The same study found that fewer than 10% of diagnosed cases received potassium hydroxide or culture confirmation.

Asia-Pacific is forecast to grow at a 5.9% CAGR through 2031, the fastest regional rate in the Tinea corporis market. India recorded 265 million cases of fungal skin disease in the Global Burden of Disease 2021 dataset. Hospital studies in India identified tinea corporis as the leading dermatophytosis presentation, representing 41% to 88% of cases at tertiary centers. A 2025 Indian study found terbinafine resistance in 60% of cultures and fluconazole resistance in 85.6% of samples. China and Japan add prescription demand, although basic clotrimazole cream products face price pressure from domestic generic suppliers.

Europe has a meaningful Tinea corporis market volume in the United Kingdom, Germany, France, Italy, and Spain, where branded azoles compete with generics and private-label products. In the United Kingdom, T. indotineae increased from 2% to 38% of dermatophyte isolates between 2018 and July 2024, then spread from London to 27 additional cities in the United Kingdom and Ireland. The Middle East and Africa also offer growth potential, but affordability and limited formal healthcare access constrain treatment penetration in parts of Sub-Saharan Africa. South America is an earlier-stage regional opportunity, with Brazil confirming its first T. indotineae case in 2024.

1. Aurobindo Pharma
2. Bausch Health
3. Bayer
4. Cipla
5. Dr. Reddy's Laboratories
6. GlaxoSmithKline
7. Glenmark Pharmaceuticals
8. Kaken Pharmaceutical Co., Ltd.
9. Lupin
10. Merck
11. Novartis
12. Perrigo Company
13. Pfizer
14. Sandoz Group AG
15. Sebela Pharmaceuticals, Inc.
16. Sun Pharmaceuticals Industries
17. Taro Pharmaceutical Industries Ltd.
18. Teva Pharmaceutical Industries
19. Viatris
20. Zydus Lifesciences Limited

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 Study Assumptions and Market Definition
• 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET LANDSCAPE

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Persistent Burden of Superficial Dermatophytosis
  • 4.2.2 Expanding OTC Access and Self-Care Treatment
  • 4.2.3 Rising Detection of Recalcitrant and Resistant Infections
  • 4.2.4 Hot-Humid Exposure, Occlusive Clothing, and Dense Contact Networks
  • 4.2.5 Dermatology Telemedicine and Pharmacy-Led Case Finding
  • 4.2.6 Short-Course and Skin-Retention Formulation Innovation
• 4.3 Market Restraints
  • 4.3.1 Terbinafine and Multidrug Resistance in Emerging Dermatophytes
  • 4.3.2 Diagnostic Misclassification and Steroid-Modified Tinea
  • 4.3.3 Treatment Nonadherence and Premature Discontinuation
  • 4.3.4 Generic Price Compression and Limited Differentiation
• 4.4 Supply Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces Analysis
  • 4.7.1 Threat of New Entrants
  • 4.7.2 Bargaining Power of Suppliers
  • 4.7.3 Bargaining Power of Buyers
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Competitive Rivalry

5 MARKET SIZE AND GROWTH FORECASTS (VALUE, USD)

• 5.1 By Drug Class
  • 5.1.1 Azoles
  • 5.1.2 Allylamines and Benzylamines
  • 5.1.3 Polyenes
  • 5.1.4 Steroids
  • 5.1.5 Anti-Infective Combinations
  • 5.1.6 Other Antifungal Classes
• 5.2 By Formulation
  • 5.2.1 Creams and Ointments
  • 5.2.2 Gels and Lotions
  • 5.2.3 Sprays and Solutions
  • 5.2.4 Powders
  • 5.2.5 Shampoos and Washes
  • 5.2.6 Other Formulations
• 5.3 By Patient Demographics
  • 5.3.1 Pediatrics
  • 5.3.2 Adults
  • 5.3.3 Geriatrics
• 5.4 By Distribution Channel
  • 5.4.1 Hospital Pharmacies
  • 5.4.2 Retail Pharmacies and Drug Stores
  • 5.4.3 Online Pharmacies
  • 5.4.4 Specialty Pharmacies
• 5.5 By Geography
  • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
  • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
  • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 Japan
    • 5.5.3.3 India
    • 5.5.3.4 Australia
    • 5.5.3.5 South Korea
    • 5.5.3.6 Rest of Asia-Pacific
  • 5.5.4 Middle East and Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East and Africa
  • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global Level Overview, Market Level Overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share, Products and Services, Recent Developments)
  • 6.3.1 Aurobindo Pharma Limited
  • 6.3.2 Bausch Health Companies Inc.
  • 6.3.3 Bayer AG
  • 6.3.4 Cipla Limited
  • 6.3.5 Dr. Reddy's Laboratories Limited
  • 6.3.6 GlaxoSmithKline plc
  • 6.3.7 Glenmark Pharmaceuticals Limited
  • 6.3.8 Kaken Pharmaceutical Co., Ltd.
  • 6.3.9 Lupin Limited
  • 6.3.10 Merck & Co., Inc.
  • 6.3.11 Novartis AG
  • 6.3.12 Perrigo Company plc
  • 6.3.13 Pfizer Inc.
  • 6.3.14 Sandoz Group AG
  • 6.3.15 Sebela Pharmaceuticals, Inc.
  • 6.3.16 Sun Pharmaceutical Industries Limited
  • 6.3.17 Taro Pharmaceutical Industries Ltd.
  • 6.3.18 Teva Pharmaceutical Industries Ltd.
  • 6.3.19 Viatris Inc.
  • 6.3.20 Zydus Lifesciences Limited

7 MARKET OPPORTUNITIES AND FUTURE OUTLOOK

• 7.1 White-Space and Unmet-Need Assessment